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Objective. The objective was to investigate pig ear skin as a surrogate for human skin in the assessment
of topical drug bioavailability by sequential tape-stripping of the stratum corneum (SC). The potential
benefits of ex vivo investigations are manifold: ethical approval is not required, multiple replicate
experiments are more easily performed, and toxic compounds can be evaluated.
Materials and Methods. Ex vivo experiments on isolated pig ears were compared with in vivo studies in
human volunteers. Four formulations, comprising the model drug, ibuprofen, in different propylene
glycol (PG)-water mixtures (25:75, 50:50, 75:25 and 100:0), were compared.
Results. Derived dermatopharmacokinetic parameters characterizing the diffusion and partitioning of
the drug in the SC ex vivo were consistent with those in vivo following a 30-minute application period.
Further, the non-steady-state ex vivo results could be used to predict the in vivo concentration profile of
the drug across the SC when a formulation was administered for 3 h (i.e., close to steady-state).
Conclusions. Taken together, the results obtained suggest that pig ear skin ex vivo has promise as a tool
for topical formulation evaluation and optimization.
KEY WORDS: dermatopharmacokinetics; stratum corneum; skin; tape-stripping; topical drug
bioavailability.
INTRODUCTION
There is an ongoing search to identify testing methods
with which to optimize topical dosage forms and to assess
topical drug bioavailability. While in vitro screening continues
to play an important role (and is relatively inexpensive and
simple to use), regulatory approval of drug delivery systems
to the skin, with few exceptions, requires clinical trials to be
performed. The latter, however, represent an onerous burden
for the development of generic dosage forms and the U.S.
Food & Drug Administration (FDA), in particular, has been
examining whether surrogate measurements may be possible
(17Y19). On the one hand, for corticosteroids, the vasocon-
striction assay (9) has been deemed an acceptable approach
to compare innovator and generic products (11,12). On the
other, for almost all other drugs used topically, the problem
remains unresolved because an easily visualized pharmaco-
dynamic response is not elicited (16).
As a consequence, various alternative techniques have
been considered, of which microdialysis and stratum corneum
(SC) tape-stripping are receiving most attention. While the
former is technically more challenging, the potential reward is
a drug concentration-time profile in a compartment presumed
to be in close communication with the site of action of most
dermatological drugs (8,20). The latter, in contrast, offers an
apparently easy and quite non-invasive methodology for skin
tissue sampling, and forms the basis of the FDA’s so-called
dermatopharmacokinetic (DPK) approach to the assessment
of topical bioavailability and bioequivalence (19). However,
validation and optimization of the procedure have not come
quickly and the proposed guidance document has been
withdrawn for re-evaluation. More recent work has
addressed at least some of the important limitations of the
DPK idea (4,5,13) and has proposed modifications to
incorporate into an improved protocol.
The goal of the research described here is not only to
contribute further to establishing the credibility of the DPK
method, but also to demonstrate that useful and relevant mea-
surements can be made on a surrogate, ex vivo skin model: the
porcine ear. Pig skin is well-accepted as a decent facsimile of
the human counterpart (14,15) and the availability of a vali-
dated model would allow extensive range-finding, develop-
mental and optimization studies to be performed before
conducting pivotal experiments in volunteers and/or patients.
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Thus, in this study, parallel DPK measurements have been
made (a) on pig ears ex vivo and (b) in normal human sub-
jects. Diffusion and partitioning parameters, which charac-
terize the rate and extent of drug absorption, have been
deduced and compared.
MATERIAL AND METHODS
Chemicals
S-(+)-Ibuprofen (Fluka, Buchs, Switzerland) was dis-
solved at saturation in various vehicles containing propylene
glycol (PG) (SigmaYAldrich, Steinheim, Germany) and
deionized water. The composition of the formulations, and
the corresponding saturation solubilities of the drug, were:
(a) 25:75 v/v PG-water, 0.303 mg/mL; (b) 50:50 v/v PG-water,
2.55 mg/mL; (c) 75:25 v/v PG-water, 37.7 mg/mL; and (d)
pure propylene glycol, 430 mg/mL. Solvents used for
ibuprofen extraction and liquid chromatographic (HPLC)
analysis were HPLC grade (SigmaYAldrich). Citric acid
monohydrate, sodium hydroxide (SigmaYAldrich) and hydro-
chloric acid 37% (Fluka, Buchs, Switzerland) were used in
buffer preparation.
The saturated solutions of ibuprofen were prepared by
stirring an excess of drug in the corresponding vehicle at
20-C (T1-C) for 96 h in 30-ml vials. After centrifugation (15
min at 3,000 rpm), the supernatant was passed through a 0.45
mm nylon Acrodisc\ filter (Pall, Basel, Switzerland). The
saturation solubility of ibuprofen was measured by HPLC
(see below) after adequate dilution. Three replicates were
performed in each solvent. In addition, a two-fold supersat-
urated 75:25 PG-water formulation was prepared by dissolv-
ing the required quantity of ibuprofen in PG and then adding
water. This system remained stable without precipitation for
at least 3 h (the duration of the longest experiment
performed).
Experimental Procedure
Twelve volunteers (9 female, 3 male, 24Y46 years) with
no history of dermatological disease participated in this study
which was approved by the University of Geneva ethical
committee. Informed consent was obtained from all subjects.
The treated sites (4  5 cm) were non-hairy regions of the
ventral forearm surface. Each treatment involved application
of 1.9 mL of ibuprofen solution, impregnated on a cellulose
gauze (Tela, Basel, Switzerland), covered by an occlusive
polyester layer (Scotchpak, 3 M, St.Louis, MN) and affixed to
the skin with an adhesive polyurethane film (Opsite, Smith &
Nephew, Hull, UK). These applications could be considered
as infinite doses from which negligible drug depletion was
anticipated during the experiment. After the required time of
contact (30 or 180 min), the patch was removed and excess
formulation was gently removed using three dry cellulose
swabs without any solvent.
Fresh pig ears were obtained from a local abattoir
(SODEXA, Annecy, France); to ensure integrity of the skin
barrier, ears were removed post-sacrifice before the carcass
was exposed to the normal high-temperature cleaning
procedure. Ears were washed with water, and any visible
hairs were trimmed carefully with scissors. The formulations
were applied to the ear in an identical fashion to that used for
human volunteers.
SC Sampling Protocol
The ibuprofen concentration profile across the SC
following application in the different vehicles was determined
by sequential removal of this outer skin layer by tape-
stripping (Scotch Book Tape, 3M, St. Paul, MN). The SC
sampling site was delimited by a template which exposed an
area smaller than that treated with the formulation. The
template was centred over the drug application site immedi-
ately before tape-stripping began. The size of the opening in
the template (2  2.5 cm) was smaller than the individual
tape-strips used. Differential weighing (Mettler AT 261
balance, Greifensee, Switzerland) of tape-strips allowed the
amount of SC removed to be estimated. From this mass, and
knowing the area of the tape, it was possible to calculate the
SC thickness removed (using a SC density of 1 g/cm3 (3)) as a
function of stripping, and hence the corresponding position
(or depth, x) within the barrier. The apparent SC thickness
(L) was determined as described elsewhere (6,7) from
measurements of transepidermal water loss (TEWL) as a
function of SC removed. This permits the drug concentration
profile to be expressed as a normalized function of relative
position within the SC (x/L) and facilitates the comparison of
data originating from different subjects (1,2,7). The TEWL
measurements were made at a site adjacent to the treated
skin because residual PG volatilization provokes
artefactually high TEWL readings (data not shown);
furthermore, each TEWL measurement requires at least 2
min during which the drug continues to diffuse into the SC,
thereby modifying the concentration profile. Ten to 16 strips
were taken from each treated site on each volunteer/pig ear,
the actual number depending upon the individual SC
thickness; however, the SC was never completely removed.
All tapes were subsequently analyzed for ibuprofen; no strips
were discarded, and it was assumed that any drug not
removed by the surface cleaning process at the end of the
treatment would eventually be bioavailable to the skin.
Extraction and Analysis of Ibuprofen in the Tape Strips
After re-weighing, the tape-strips were rolled and placed
in 1.5 ml HPLC vials. Ibuprofen was quantitatively extracted
with a 90:10 mixture of acetonitrile and 1 M hydrochloric acid
during 12 h. Validation of this procedure was evaluated by
spiking tape-stripped samples of untreated SC with known
amounts of drug in solution, chosen to bracket the expected
range of concentrations to be found in the in vivo samples. It
was not necessary to filter the tape-strip extraction solutions
which were completely clear and protein-free (Biorad\ pro-
tein assay, Hercules, CA). Ibuprofen was analyzed by HPLC
using a Merck Lichrospher 100 RP18 (5 mm) column
(Darmstadt, Germany) and a model 486 absorbance detector
from Waters (Milford, USA) at 227 nm. The isocratic mobile
phase was a 55:45 (v/v) mixture of acetonitrile and 0.1 M cit-
rate buffer at pH 2.4. At a flow rate of 1.2 ml/min, and at room
temperature, the retention time of ibuprofen was about 5 min.
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Peak recording and data processing were performed with the
built-in system manager. Ibuprofen was determined using
the AUC method and calibration plots were generated with
the neat compound. The quantification limit was 0.5 mg/ml.
Experimental Strategy and Data Analysis
Comparison of Formulations After a 30-Minutes
Application Time
The SC concentration (Cx) versus depth (x) profiles of
ibuprofen were fitted to the following solution of Fick’s
second law of diffusion:
Cx ¼ KCv 1 x
L
 
 2

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The applicable boundary conditions are (a) the applied
drug concentration (Cv) remains constant during the treat-
ment period (t); (b) the viable epidermis acts as a perfect sink
for the drug; and (c) the SC contains no drug at t = 0. The
fitting generates values of K and D/L2. The former is the SC/
vehicle partition coefficient, a thermodynamic parameter
reflecting the relative affinity of the drug for SC over the
vehicle. The second parameter has units of (time)j1 and is a
first-order kinetic constant describing drug diffusion across
the SC. Integration of Eq. (1) across the SC thickness (i.e.,
from x/L = 0 to x/L = 1) provides an expression for the area
under the SC concentration versus relative depth profile
(AUC) which equals the total amount of drug present in the
membrane divided by the volume of this compartment.
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Prediction of the Amount of Ibuprofen in the SC at 3 h
The saturated and supersaturated (2 degrees of satura-
tion, 2DS) drug formulations in 75:25 v/v PG-water were
used in this experiment. The ibuprofen concentration-SC
depth profiles at 30 min were evaluated independently using
Eq. (1), generating best-fit values of K and D/L2. From the
D/L2 values obtained, it was estimated that õ3 h (=[2.7IL2]/
6D) would be necessary to achieve steady-state transport.
Then, using Eq. (2) with the K and D/L2 values obtained
from the 30-minute experiment, the AUC at 3 h was
predicted. DPK experiments were subsequently performed
with an application time of 3 h and the AUC was determined
and compared to the prediction.
RESULTS AND DISCUSSION
It is first noted that the SC levels of ibuprofen following
a 30-minute application of the 25:75 v/v PG-water formula-
tion were very low and fell below the limit of HPLC
detection after the first few tape-strips. Data (not shown)
from these experiments were not considered further, there-
fore. Figure 1 summarizes the SC concentration-depth
profiles both in vivo in human subjects, and ex vivo in pig
ear skin, following treatment (again for 30 min) with the
three other PG-water vehicles tested (50:50, 75:25 and 100:0,
respectively). In both cases, variability was quite low,
suggesting that the methodology is robust. It is also apparent
that the drug was delivered into the SC more effectively as
the percentage of PG in the formulation increased. Impor-
tantly, there was good visual consistency between the in vivo
and ex vivo profiles, indicating that the pig ear may indeed be
a useful model in this context.
A more objective evaluation of this conclusion was
facilitated by fitting the individual profiles to Eq. (1) and
comparison of the resulting partitioning and diffusivity
parameters (K and D/L2, respectively). Table I presents the
average (Tstandard deviation (SD)) results for K and D/L2
derived from fitting Eq. (1) to the individual profiles in Fig. 1.
Also included in this Table are the values of AUC (again given
as mean T SD) calculated using Eq. (2) and the respective K
and D/L2 for each subject/pig ear. Immediately striking is
that the diffusion kinetic is both independent of the
formulation and statistically identical in vivo and ex vivo.
The values of K and AUC, on the other hand, are
significantly influenced by the nature of the formulation, a
point discussed further below. Nevertheless, for each
formulation, the in vivo and ex vivo results for K and AUC
compare well. While there are some statistically significant
differences noted (see Table I), the absolute values (human
versus pig ear) never deviate by as much as a factor of 2; that
is, it would be difficult to argue that this level of
Bdisagreement^ would be important in practice. The
possibility that the significant differences observed were
simply the result of differences in the SC thickness of
human and porcine SC was examined by pooling more than
80 separate measurements of L in the two skins (Fig. 2). The
thicknesses were log-normally distributed about median
values of 11.0 and 8.2 mm for human and pig ear SC,
respectively. In vivo, human SC thicknesses ranged from a
minimum value of 7.8 mm to a maximum of 18.6 mm; for pig
ear ex vivo, the range was 4.1 to 16.1 mm. While there is
obvious (and not unexpected) variability in the values found,
and despite a statistically significant difference between the
human and porcine barriers, it is not possible to correlate
systematically the small divergences in K and AUC in Table I
to the differences in L. Lastly, for the 75:25 v/v PG-water
formulation, the two-fold supersaturated vehicle performed
as expected, resulting in identical diffusion and partitioning
parameters as the simply saturated one, but producing a
significantly, and approximately two-times higher, AUC.
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From the values of K and D/L2, together with the
corresponding SC thickness (L) determined for each subject/
pig ear, it is possible to deduce the permeability coefficient
(Kp) of ibuprofen across the SC from each of the
formulations tested using Eq. (3):
Kp ¼ K D
L2
L ¼ KD
L
ð3Þ
Likewise, knowing Kp and the concentration of drug in
the vehicle (Cv), the steady-state flux (Jss) across the SC can
be estimated:
Jss ¼ KpCv ¼ KD
L
Cv ð4Þ
The results are collected in Table II. Once again, there
were no significant differences between either Kp or Jss when
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Fig. 1. In vivo human (left panels) and ex vivo pig ear (right panels) SC concentration versus relative depth profiles of
ibuprofen following 30 min treatment with different PG-water formulations. The lines drawn through the data represent
the best fits of Eq. (1) to each set of results.
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comparing the in vivo human data with the corresponding ex
vivo values; even when statistical significance was achieved,
the Freal-life_ impact of the difference would probably be
negligible.
Differences in both Kp and Jss were apparent, however,
whether one considers either the in vivo or ex vivo results,
between the various PG-water compositions examined. This
observation was anticipated, of course, because of the differ-
ences in the SC-water partition coefficient and AUC
reported in Table I. Theory predicts that the steady-state
flux of a drug across a membrane from a saturated solution
should be independent of the composition of the solution as
long as the latter does not itself change in some way the
properties of the barrier. In terms of Fick’s first law, as
expressed by Eq. (4), this means that the increases in Cv
resulting from incorporation of progressively more PG into
the formulation should be exactly balanced by a
corresponding decrease in K, which can be defined as the
ratio of drug solubilities in the SC and in the vehicle:
K ¼ CsatSCCsatv ð5Þ
Table I shows that K does indeed decrease as the
percentage of PG in the vehicle increases, reflecting the fact
that ibuprofen prefers the cosolvent to water. However, this
decrease is less steep than the increase in drug solubility in
the vehicle, and Jss (and AUC) are therefore greater for the
formulations with progressively higher levels of PG. This
deduction can be appreciated by substitution of Eq. (5) into
Eq. (4), recalling that all the vehicles studied in this work
were saturated with drug. It follows that PG must be altering
the solubility of ibuprofen in the SC; specifically, it appears
that uptake of PG into the SCVwhich increases with
increasing amounts of the cosolvent in the formula-
tionVenhances the drug’s solubility in the barrier (i.e., CsatSC )
and results in improved penetration and transport. The
literature provides support for this explanation, in that it
has been shown that PG can replace water at its binding sites
in the SC intercellular spaces (10) and that it is capable of
effectively Bdragging^ drug into and through the SC, thereby
increasing permeation (21).
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Fig. 2. Comparison between the apparent thickness of human SC in
vivo (mean T SD = 11.7 T 3.2; n = 35) and that of excised porcine ear
SC ex vivo (mean T SD = 8.5 T 3.0; n = 49). The individually displayed
values are log-normally distributed and show a statistically significant
difference (MannYWhitney test, p < 0.0001).
Table II. Estimated Permeability Coefficients (Kp) and Steady-State
Fluxes (Jss) of Ibuprofen Across SC Following Drug Application in
Various PG-Water Vehicles either in Vivo in Human Volunteers or
ex Vivo on Pig Ear Skin (Mean T SD, n = 7Y9)
Formulation Test system
104 Kp
(cm hj1)a Jss (mg cm
2 hj1)b
50:50 PG-H2O In vivo 26 T 10
c 7 T 3c
Ex vivo 21 T 14c 5 T 4c
75:25 PG-H2O In vivo 4 T 1
c 15 T 5c
Ex vivo 4 T 2c 13 T 6c
75:25 PG-H2O
(2 supersat’d)
In vivo 5 T 2c 33 T 12c
Ex vivo 3 T 0.4c 21 T 3c
100:0 PG-H2O In vivo 1.0 T 0.5
d 45 T 21d
Ex vivo 0.3 T 0.1d 13 T 6d
a Determined from Eq. (3) using the measured SC thickness (L) and
fitted D/L2 and K for each subject/pig ear.
b Determined from Eq. (4) using the appropriate Cv (see Materials
and Methods) and the Kp values in this Table.
c For each formulation, each pair of values are not significantly
different (p > 0.05, unpaired t-test).
d Values statistically different ( p<0.05, unpaired t-test).
Table I. Diffusivity and Partition Parameters, and Calculated AUCs (Eqs. (1) and (2)) Describing Ibuprofen Uptake into SC Following a 30-
Minute Application of Various PG-Water Vehicles either in Vivo in Human Volunteers or ex Vivo on Pig Ear Skin (Mean T SD, n = 7Y9)
Formulation Test system D/L2 (hj1) a,b Ka AUC (M)c
50:50 PG-H2O In vivo 0.16 T 0.07 14 T 2
d 0.05 T 0.01d
Ex vivo 0.16 T 0.14 21 T 6d 0.07 T 0.04d
75:25 PG-H2O In vivo 0.12 T 0.05 2.8 T 0.3
d 0.13 T 0.02d
Ex vivo 0.15 T 0.07 3.0 T 0.4d 0.16 T 0.05d
75:25 PG-H2O (2 supersat’d) In vivo 0.19 T 0.09 2.4 T 0.4d 0.26 T 0.05d
Ex vivo 0.14 T 0.03 2.7 T 0.5d 0.28 T 0.08d
100:0 PG-H2O In vivo 0.13 T 0.06 0.56 T 0.07
e 0.33 T 0.07e
Ex vivo 0.14 T 0.09 0.33 T 0.08e 0.18 T 0.05e
a Values from the best-fits of Eq. (1) to the results in Fig. 1.
b ANOVA reveals no significant differences between any of the D/L2 values.
c Determined from Eq. (2) using the corresponding fitted D/L2 and K for each subject/pig ear.
d For each formulation, each pair of values are not significantly different ( p > 0.05, unpaired t-test).
e Values statistically different (p < 0.05, unpaired t-test).
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In a final component of this study, the partitioning and
diffusivity parameters derived from the experiment in which
ibuprofen was applied in a 75:25 v/v PG-water vehicle (at
both 1 and 2 degrees of saturation) were used, with Eq. (2),
to predict the AUC when the duration of exposure was
increased to 3 h (at which time, it was anticipated that drug
transport would have reached close to steady-state). These
predictions were then compared to the results of subsequent-
ly performed experiments (Fig. 3). Table III summarizes the
outcome of this investigation and indicates that the predic-
tions, both in vivo and ex vivo, and from a supersaturated
formulation, were remarkably close to (and not significantly
different from) the experimental results. It can be concluded
once again, therefore, that pig ear skin ex vivo is a good
model for the human barrier in vivo, and that relatively
short-contact studies may be reliably extrapolated to predict
an important fraction of the absorption phase of a DPK
profile.
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Fig. 3. SC concentration versus relative depth profiles of ibuprofen following 3 h treatment with a 75:25 v/v PG-water
formulation in which the drug was present at either 1 or 2 degrees of saturation. The left panels show the results from human
in vivo experiments (n = 6Y7); the right panel presents the data from ex vivo measurements on isolated pig ears (n = 6).
Table III. Comparison Between Predicted and Experimental Values of Ibuprofen AUC Following a 3-Hour Application of Saturated and
Two-Fold Supersaturated 75:25 v/v PG-Water Formulations in Vivo in Human Volunteers and ex Vivo on Pig Ear Skin (Mean T SD, n = 7Y9)
Formulation Test system Predicted AUC at 3 h (M)a Experimental AUC at 3 h (M)b Deduced K 3 h (M)c
75:25 PG-H2O (saturated) In vivo 0.24 T 0.02
d 0.25 T 0.04d 3.0 T 0.3e
Ex vivo 0.26 T 0.04d 0.23 T 0.07d 2.9 T 0.9e
75:25 PG-H2O (2 supersat’d) In vivo 0.41 T 0.06d 0.49 T 0.07d 3.1 T 0.4e
a Calculated using Eq. (2) and the corresponding mean (TSD) K and D/L2 values determined following a 30-minute application of the same
formulations (see Table I).
b Determined by graphical integration of the SC concentration versus relative SC depth data.
c Determined from the y-axis intercepts of the profiles in Fig. 3 and the corresponding values of Cv for each formulation.
d No significant difference between predicted and experimental values (p > 0.05, unpaired t-test).
e Values are not statistically different from the corresponding results determined after a 30-minute application of the same formulations (see
Table I) ( p > 0.05, unpaired t-test).
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CONCLUSIONS
This research has revealed three significant findings: [1]
The ex vivo pig ear model appears to be a quantitative and
reproducible model for DPK studies of topical bioavailabil-
ity, producing data that are comparable to those observed in
vivo in human subjects. An important caveat here is that the
ex vivo system lacks, of course, a functioning cutaneous
circulation; as a consequence, while the approach will be
representative of short-contact exposures, it may be less
adequate for longer application times, particularly for drugs
of high lipophilicity (where the isolated pig ear may not
provide appropriate Fsink_ conditions). [2] Formulations
containing high PG content apparently result in significant
uptake of the cosolvent into the SC, and this can lead to (a)
an increased saturation solubility of a drug (such as ibupro-
fen) in the membrane, and (b) as a result, enhanced delivery
into and through the skin. [3] Short-contact DPK experi-
ments can be used to derive diffusion and partitioning param-
eters that are subsequently able to predict drug penetration
into the SC following longer periods of application.
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